pharma · Moderate to severe systemic lupus erythematosus · Lupus Erythematosus, Systemic
Viatris Pharmaceuticals Co
Viatris Pharmaceuticals Co.,
Viatris Pharmaceuticals Co trial registry — 9 ClinicalTrials.gov studies with program phase, status, and indication context.
FR HQ
4 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- FR
- Employees
- 4
- Programs
- 8
- Drugs
- 23
- Patents
- 0
Viatris Pharmaceuticals Co clinical trials
Registry index of 9 ClinicalTrials.gov studies linked to Viatris Pharmaceuticals Co programs — each row shows trial ID, program name, phase, status, and indication.
Viatris Pharmaceuticals Co trial registry — 9 ClinicalTrials.gov studies with program phase, status, and indication context.
Recent trial activity
Latest clinical program signals indexed for Viatris Pharmaceuticals Co.
-
ID-076A301 — Phase 3
Clinical update -
ID-064-108 — Phase 1
Clinical update -
Cenerimod — Phase 3
Clinical update -
Cenerimod 4 mg — Phase 3
Clinical update -
Cenerimod 4 mg, Cenerimod matching placebo — Phase 3
Clinical update -
Cenerimod matching placebo, Cenerimod 4 mg — Phase 3
Clinical update -
Selatogrel — Phase 3
Clinical update -
Selatogrel — Phase 2
Clinical update
Trial registry
-
CTIS ↗ -
CTIS ↗ - 2024-515870-28-00CTIS ↗
Cenerimod matching placebo, Cenerimod 4 mg
Moderate to severe systemic lupus erythematosus
- 2024-515871-37-00CTIS ↗
Cenerimod 4 mg, Cenerimod matching placebo
Moderate to severe systemic lupus erythematosus
-
CTIS ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗ -
CT.gov ↗